Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21338840 | 0.91 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL24446021 | 0.90 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL24445771 | 0.89 | ADORA2A (0.69) | ADORA2A | |
| SCHEMBL24445775 | 0.89 | ADORA2A (0.77) | ADORA2A | |
| SCHEMBL21887098 | 0.89 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL24445767 | 0.89 | ADORA2A (0.62) | ADORA2A | |
| SCHEMBL25565137 | 0.88 | ADORA2A (0.76) | ADORA2A | |
| SCHEMBL24445996 | 0.88 | ADORA2A (0.72) | ADORA2A | |
| SCHEMBL25541278 | 0.88 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL20522124 | 0.88 | ADORA2A (0.71) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165863-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2023-06-01 | — | — | US | disclosed |
| EP-4112623-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| EP-3601296-B1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165863-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.